Original Publication Date: 5 April, 2014
Publication / Source: International Journal of Hematologic Oncology
Authors: Kehinde Adekola & Muzaffar Qazilbash
Current treatment for newly diagnosed multiple myeloma (MM) can be divided into different phases: induction, high-dose chemotherapy and autologous hematopoietic stem cell transplantation (auto-HSCT), consolidation and maintenance. The use of auto-HSCT, immunomodulatory agents (IMiDs) and proteasome inhibitors (PIs) in the treatment of MM have greatly improved the progression-free survival (PFS) and overall survival (OS) of these patients in the last 10–15 years . Even with recent progress in therapy, almost all MM patients eventually relapse. To overcome this problem, approaches such as post-auto-HSCT consolidation and maintenance are being explored to prolong the duration of remission and delay disease progression [2–4].